The present status of malaria chemotherapy: mefloquine, a novel antimalarial.
D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D001029:Aotus trivirgatus; D055598:Chemical Phenomena; D002621:Chemistry; D002738:Chloroquine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004285:Dogs; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000469:parasitology; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008253:Macaca mulatta; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D015767:Mefloquine; D051379:Mice; D010962:Plasmodium berghei; D010963:Plasmodium falciparum; D010965:Plasmodium malariae; D010966:Plasmodium vivax; D011319:Primaquine / Q000627:therapeutic use; D002727:Proguanil / Q000627:therapeutic use; D011487:Protein Conformation; D011739:Pyrimethamine / Q000627:therapeutic use; D011804:Quinolines / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use*; D051381:Rats; D013237:Stereoisomerism; D013552:Swine
D000962:Antimalarials; D011804:Quinolines; D000655:Amodiaquine; D002738:Chloroquine; D011319:Primaquine; D002727:Proguanil; D015767:Mefloquine; D011739:Pyrimethamine